The combination of Merck & Co’s checkpoint inhibitor Keytruda and Seagen/Astellas’ antibody-drug conjugate Padcev has been approved by the FDA as an alternative to che
Less than a year after an embarrassing departure from Seagen following an arrest for alleged domestic violence – which never resulted in formal charges – Clay Siegall has
The long-running rumour that Merck & Co was building up to a takeover bid for Seagen has so far proved unfounded, and now Pfizer is said to be casting its eye over the
Daiichi Sankyo has succeeded in a bid to convince the US Patent and Trademark Office (PTO) to take another look at a patent held by Seagen that was previously deemed to ha
GSK’s Arexvy has become the first vaccine for respiratory syncytial virus (RSV) to be approved in the EU, getting the nod from the European Commission for use in older adu
Health systems globally have reached a critical inflexion point, where ageing populations and tightening budgets mean we can no longer continue to purely treat late-stage symptomatic diseas